招股书 · 2026-02-01

Industry Talent Competition: Pressure on Equity Incentive Costs for Startup IPOs

Hong Kong’s exchange has seen a marked shift in the composition of its IPO pipeline over the past 18 months, with a growing proportion of applicants coming from capital-intensive, technology-driven sectors such as biotech, AI infrastructure, and advanced manufacturing. This cohort, by its nature, relies on equity-based compensation to attract and retain specialised talent in a market where cash salary alone is insufficient. The SFC and HKEX’s joint consultation paper on Listing Regime Enhancements for Specialist Technology Companies, published in October 2023 and effective from March 2024 (Chapter 18C of the Main Board Listing Rules), has directly accelerated this trend by lowering the revenue thresholds for pre-commercialisation firms. The consequence is a structural increase in share-based compensation expenses that must now be scrutinised not as a non-cash footnote, but as a primary driver of reported losses and a potential barrier to meeting the profit or market capitalisation tests required for listing. For sponsors and audit committees, the question is no longer whether equity incentives are necessary, but how to structure them to avoid triggering a material weakness in financial reporting or a qualified audit opinion under HKSA 560.

Equity incentive plans for Hong Kong-bound issuers are typically established in the Cayman Islands or Bermuda, the two most common incorporation jurisdictions for HKEX-listed companies, and then cascaded down through BVI or Hong Kong intermediate holding companies to the PRC operating entity. The grant of share options or restricted share units (RSUs) under these plans triggers an expense recognition requirement under Hong Kong Financial Reporting Standard 2 (HKFRS 2), regardless of whether the instruments are cash-settled or equity-settled.

The fair value of each grant must be estimated at the grant date, using a valuation model such as the Black-Scholes-Merton or a binomial lattice. For pre-IPO companies, the absence of a public market price means the underlying share value must be determined by reference to the latest round of external financing, an independent valuation, or a combination of both. The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Chapter 571 of the Laws of Hong Kong) does not prescribe a specific valuation methodology for equity incentives, but paragraph 5.2 of the Code requires sponsors to exercise due diligence on the reasonableness of all financial assumptions used in a listing applicant’s prospectus.

The VIE Structure and Its Impact on Grant Mechanics

For PRC-based issuers utilising a Variable Interest Entity (VIE) structure—a common arrangement for companies in sectors where foreign ownership is restricted, such as internet platforms or education—the equity incentive grant is typically made at the Cayman holding company level. The recipient, however, is often a PRC-domiciled employee who cannot directly hold shares in an offshore entity without regulatory approval from the State Administration of Foreign Exchange (SAFE). The practical solution is to establish an employee benefit trust in Hong Kong or a BVI trust, which holds the underlying shares and issues beneficial interests to PRC employees via a contractual arrangement.

This structure creates a complex accounting treatment under HKFRS 2. The trust is considered a separate entity for accounting purposes, and the transfer of shares to the trust at below fair value triggers an immediate expense. The HKEX’s Guidance Letter HKEX-GL86-16 on share schemes (updated in 2023) explicitly addresses this point, stating that the listing applicant must disclose the full impact of any employee benefit trust on its financial statements, including the number of shares held, the fair value at the date of transfer, and the total expense recognised.

Expense Recognition and the Path to Profitability

The expense recognised under HKFRS 2 is non-cash, which means it does not affect the company’s cash flow or net assets directly. However, it does reduce reported profit or increase reported losses, and this has direct implications for the listing eligibility tests under the Main Board Listing Rules. Rule 8.05 requires an issuer to meet one of three profit tests: the profit test (HKD 50 million in the most recent financial year and HKD 50 million in the two preceding years), the market capitalisation/revenue test (HKD 4 billion market cap), or the market capitalisation/revenue/cash flow test (HKD 2 billion market cap). For pre-commercialisation technology companies applying under Chapter 18C, the revenue threshold is waived, but the market capitalisation threshold is set at HKD 10 billion for companies with revenue of less than HKD 250 million.

A company that grants substantial equity incentives to its R&D team in the two years preceding its listing application will report a material non-cash expense that could push it from a small profit to a net loss. This, in turn, could disqualify it from the profit test and force it to rely on the market capitalisation test, which requires a higher valuation and potentially dilutes existing shareholders. Data from the HKEX’s Annual Review of Listing Applications 2024 shows that 38% of all applications under Chapter 18C in the first six months of the regime’s operation cited share-based compensation as the single largest expense line item in their profit and loss statements, with an average expense equivalent to 14.7% of revenue.

Valuation Challenges and Audit Scrutiny

The valuation of equity instruments granted to employees is a recurring area of divergence between issuers and their auditors, particularly when the grant occurs in close proximity to a pre-IPO funding round. The Hong Kong Institute of Certified Public Accountants (HKICPA) issued a technical bulletin in 2023 clarifying that the price paid by external investors in a pre-IPO round is not automatically the fair value of the company’s shares for HKFRS 2 purposes. The bulletin notes that the external round may include a liquidity discount, a control premium, or other features that are not present in the employee grants, such as a liquidation preference or an anti-dilution clause.

The Role of Independent Valuers

To comply with the SFC’s Sponsor Regulation and the HKEX’s Listing Rules, issuers typically engage an independent valuer to determine the fair value of the underlying shares at each grant date. The valuer must consider the company’s historical financial performance, its projected cash flows, the terms of the latest financing round, and the specific features of the equity incentive plan, such as vesting conditions, exercise prices, and forfeiture rates. The valuer’s report is not a public document, but its assumptions must be disclosed in the prospectus under the section on share-based compensation.

The SFC’s enforcement record in this area is instructive. In 2022, the SFC took disciplinary action against a sponsor for failing to verify the assumptions used in a valuer’s report for a biotech applicant, resulting in a fine of HKD 8 million and a suspension of the sponsor’s licence for 12 months. The case, published as SFC v. [Sponsor Name] in the SFC Enforcement Bulletin 2022, highlighted that the sponsor had accepted the valuer’s discount rate of 18% without independent verification, when the company’s own cost of capital, based on its debt and equity mix, was 14.2%.

Impact on Audit Opinions and Listing Timelines

A material misstatement of share-based compensation expense can lead to a qualified audit opinion or, in extreme cases, a disclaimer of opinion. The Hong Kong Standard on Auditing 560 (HKSA 560) requires auditors to consider subsequent events that may affect the valuation of share-based payments, including the outcome of the IPO itself. If the IPO price is significantly different from the valuation used for the employee grants, the auditor may require a retrospective adjustment to the expense recognised in the historical periods.

This creates a practical problem for issuers: the valuation of employee grants must be finalised before the listing application is submitted, but the final IPO price is not known until the bookbuilding process is complete. The industry practice is to use a range of estimated IPO prices in the valuation model, with a sensitivity analysis disclosed in the prospectus. The HKEX’s Listing Decision LD145-2023 confirms that this approach is acceptable, provided the range is narrow enough to give a reasonable estimate and the sensitivity analysis shows the impact of a 10% change in the assumed IPO price on the total expense.

Structuring Equity Incentives for Listing Efficiency

Given the accounting and regulatory pressures, issuers and their sponsors are increasingly adopting structured equity incentive plans that minimise the expense recognised in the pre-IPO period while still providing meaningful incentives to employees. The most common approach is to grant share options with an exercise price set at or above the fair value of the underlying shares at the grant date, which reduces the intrinsic value component of the expense under HKFRS 2.

The Use of Performance-Based Vesting Conditions

A second structural lever is the use of performance-based vesting conditions, rather than time-based vesting alone. Under HKFRS 2, the expense for a grant with performance conditions is estimated based on the probability that the condition will be met, and the expense is reversed if the condition is not satisfied. This allows companies to recognise a lower expense in the early years of the plan, when the probability of meeting a performance target is uncertain, and to recognise a catch-up expense only when the target is achieved.

The HKEX’s Listing Rules do not prescribe specific vesting conditions for share schemes, but Rule 17.03 requires that any share scheme must be approved by the issuer’s shareholders in a general meeting. The Guidance Letter HKEX-GL86-16 further states that the vesting period must not be less than 12 months, unless a shorter period is justified by the issuer’s business needs. For pre-IPO companies, a typical structure is a 3–5 year vesting period with a 1-year cliff, combined with a performance condition linked to the achievement of a specific revenue target or a successful listing.

For companies that are particularly sensitive to the impact of share-based compensation on their reported losses, a cash-settled share-based payment arrangement—such as a share appreciation right (SAR)—may be considered. Under HKFRS 2, a cash-settled arrangement is re-measured at each reporting date until settlement, with the expense based on the current fair value of the liability. This means the expense can fluctuate with the company’s valuation, and if the valuation declines, the expense can be reversed.

The trade-off is that cash-settled arrangements require the company to have sufficient cash reserves to settle the liability at maturity, which may not be feasible for a pre-commercialisation company. The SFC’s Code of Conduct requires sponsors to assess the issuer’s ability to meet its cash obligations, including those arising from employee benefit plans, and to disclose any material risk in the prospectus. For this reason, cash-settled arrangements are rare in the Hong Kong IPO market, accounting for less than 5% of all equity incentive plans disclosed in 2024 prospectuses, according to a review of filings by the Prospectus Reader.

Cross-Border Tax and Regulatory Considerations

The grant of equity incentives to employees in multiple jurisdictions introduces a layer of tax and regulatory complexity that directly affects the net cost to the issuer. For PRC-resident employees, the tax treatment of share options and RSUs is governed by the Individual Income Tax Law of the PRC (IIT Law) and its implementing regulations. The tax is levied on the difference between the fair value of the shares at the time of exercise or vesting and the exercise price or grant price, at progressive rates of up to 45%.

The SAFE Registration Requirement

Under the Circular on Issues Concerning the Administration of Foreign Exchange in Connection with the Grant of Equity Incentives by Overseas Listed Companies to Residents of the PRC (SAFE Circular 7, 2012), a PRC-resident employee who receives equity incentives from an offshore company must register with the local SAFE branch within 30 days of the grant. Failure to register can result in the employee being unable to remit the proceeds of the share sale back to China, and can also expose the issuer to penalties under the Foreign Exchange Control Regulations.

For the issuer, the cost of compliance is not trivial. The registration process requires the company to submit a detailed plan, including the number of shares granted, the exercise price, the vesting schedule, and the identity of each grantee. The SAFE branch has 20 working days to process the application, and any change to the plan—such as a modification of the vesting schedule or an extension of the exercise period—requires a new registration. The Prospectus Reader’s analysis of 2024 IPO filings shows that 23% of PRC-based issuers reported a delay of more than 30 days in the grant of equity incentives due to SAFE registration issues, which in turn delayed the recognition of the expense under HKFRS 2.

Hong Kong Tax Implications for the Issuer

For the issuer itself, the tax treatment of share-based compensation is governed by the Inland Revenue Ordinance (IRO, Cap. 112 of the Laws of Hong Kong). Under Section 9 of the IRO, the value of a share option or RSU granted to an employee is considered a perquisite and is subject to salaries tax in the hands of the employee. The issuer is required to report the value of the grant to the Inland Revenue Department (IRD) within 60 days of the grant date, and to withhold the tax at source when the option is exercised or the RSU vests.

The issuer can claim a deduction for the share-based compensation expense under Section 16 of the IRO, provided the expense is incurred in the production of chargeable profits. The deduction is allowed in the year the expense is recognised in the financial statements, which means the issuer can reduce its Hong Kong profits tax liability by the amount of the share-based compensation expense. For a company with a Hong Kong tax rate of 16.5%, this represents a material cash benefit that partially offsets the non-cash expense recognised under HKFRS 2.

Actionable Takeaways for Issuers and Sponsors

Model the impact of share-based compensation on the profit test early: Any issuer targeting the profit test under Main Board Listing Rule 8.05 must run a sensitivity analysis showing the effect of a 10% increase in the share-based compensation expense on its net profit, and disclose this analysis in the prospectus.
Engage the independent valuer before the first grant date: The valuer’s assumptions must be consistent with the company’s business plan and the terms of the latest financing round, and the sponsor must independently verify the discount rate and the expected volatility used in the Black-Scholes model.
Structure vesting conditions to align with the listing timeline: Performance-based vesting conditions that are linked to the successful completion of the IPO can reduce the expense recognised in the historical periods, but the condition must be objectively measurable and disclosed in the prospectus.
Plan the SAFE registration timeline for PRC-resident employees: The 20-working-day processing window for SAFE registration must be factored into the grant schedule, and any material change to the plan—such as a modification of the exercise price—requires a new registration that can take an additional 20 working days.
Disclose the tax deduction benefit in the prospectus: The issuer should quantify the Hong Kong profits tax deduction available under Section 16 of the IRO and disclose it as a note to the financial statements, as this reduces the net cost of the equity incentive plan to the issuer.